Victory Capital Management
BBIO icon

Victory Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Victory Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.6M Sell
208,823
-45,184
-18% -$3.16M 0.01% 983
2026
Q1 		$18.9M Sell
254,007
-23,074
-8% -$1.67M 0.01% 892
2025
Q4 		$21.2M Sell
277,081
-202,599
-42% -$13.3M 0.01% 852
2025
Q3 		$24.9M Buy
479,680
+141,800
+42% +$6.92M 0.01% 818
2025
Q2 		$14.6M Buy
337,880
+258,029
+323% +$9.38M 0.01% 990
2025
Q1 		$2.76M Buy
79,851
+14,825
+23% +$500K ﹤0.01% 1452
2024
Q4 		$1.78M Sell
65,026
-312,156
-83% -$8.07M ﹤0.01% 1540
2024
Q3 		$9.6M Sell
377,182
-5,535
-1% -$145K 0.01% 1119
2024
Q2 		$9.69M Buy
382,717
+34,360
+10% +$939K 0.01% 1091
2024
Q1 		$10.8M Sell
348,357
-111,212
-24% -$3.78M 0.01% 1040
2023
Q4 		$18.6M Buy
459,569
+24,156
+6% +$725K 0.02% 805
2023
Q3 		$11.5M Sell
435,413
-118,320
-21% -$3.36M 0.01% 965
2023
Q2 		$9.52M Buy
553,733
+541,690
+4,498% +$8.15M 0.01% 1063
2023
Q1 		$200K Sell
12,043
-73,253
-86% -$854K ﹤0.01% 2250
2022
Q4 		$650K Sell
85,296
-66,625
-44% -$638K ﹤0.01% 1923
2022
Q3 		$1.51M Buy
151,921
+50,556
+50% +$525K ﹤0.01% 1541
2022
Q2 		$920K Buy
101,365
+949
+0.9% +$7.94K ﹤0.01% 1787
2022
Q1 		$989K Sell
100,416
-1,603
-2% -$16.5K ﹤0.01% 1819
2021
Q4 		$1.7M Buy
102,019
+91,010
+827% +$3.85M ﹤0.01% 1612
2021
Q3 		$516K Sell
11,009
-283
-3% -$15.2K ﹤0.01% 2158
2021
Q2 		$688K Sell
11,292
-1,291
-10% -$73.7K ﹤0.01% 2034
2021
Q1 		$775K Buy
12,583
+1,290
+11% +$84.4K ﹤0.01% 2022
2020
Q4 		$803K Buy
11,293
+789
+8% +$38.1K ﹤0.01% 1881
2020
Q3 		$394K Sell
10,504
-69,456
-87% -$2.19M ﹤0.01% 2045
2020
Q2 		$2.61M Sell
79,960
-7,026
-8% -$214K ﹤0.01% 1350
2020
Q1 		$2.52M Sell
86,986
-3,304
-4% -$102K ﹤0.01% 1261
2019
Q4 		$3.17M Sell
90,290
-711,699
-89% -$19.7M ﹤0.01% 1347
2019
Q3 		$17.2M Buy
801,989
+170,200
+27% +$4.71M 0.02% 849
2019
Q2 		$17M Buy
+631,789
New +$17.2M 0.03% 655

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Victory Capital Management's BBIO Position: Q2 2026 in Review

Victory Capital Management reduced its BridgeBio Pharma (BBIO) stake by 18% in Q2 2026, selling an estimated $3.16M and leaving 208,823 shares worth $15.6M. The position accounts for 0.01% of the portfolio, ranked #983.

Victory Capital Management first reported a position in BBIO in Q2 2019 and has held it in 29 quarters since. The position peaked at $24.9M in Q3 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Victory Capital Management held 208,823 shares of BridgeBio Pharma worth $15.6M as of Q2 2026.
  • Victory Capital Management sold 45,184 BridgeBio Pharma shares in Q2 2026, an estimated $3.16M.
  • BridgeBio Pharma made up 0.01% of Victory Capital Management's portfolio in Q2 2026, its #983 holding.
  • Victory Capital Management first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 29 quarters since.
  • Victory Capital Management's BridgeBio Pharma position peaked at $24.9M in Q3 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.